UNSPSC 51184013: Glybuthiazol

This classification denotes an anti-diabetic agent with the molecular formula C12H16N4O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 35421N8E8W, chemically known as sulfanilamide, n(sup 1)-(5-tert-butyl-1,3,4-thiadiazol-2-yl)- but more generally known as glybuthiazol, which bears US NIH Compound Identifier 10811. European Medicines Agency schedules Glybuthiazol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07946MIG.

UNSPSC 51184013 Glybuthiazol is a Commodity code encompassing individual pharmaceutical active ingredients and finished drug formulations supplied to state and local government health systems, correctional facilities, and other public health agencies. State and local procurement under this code focuses on establishing framework agreements with pharmaceutical manufacturers to supply generic multi-source drugs and over-the-counter products through authorized wholesaler networks, with pricing, product compliance, and supply-chain security as primary evaluation criteria. Issuing bodies include state cooperative purchasing alliances administering agreements on behalf of multiple participating jurisdictions, departments of health and human services, departments of administration procurement offices, and individual state and local health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the cooperative-purchasing model under which multiple states leverage combined purchasing power to negotiate pharmaceutical pricing and establish vendor panels.

MMCAP's January 2026 Request for Proposal for Generic Multi-Source Pharmaceuticals and OTC Products, due March 26, 2026, exemplifies current activity under the code. The solicitation seeks manufacturers willing to supply identified pharmaceutical products identified by National Drug Code, SKU, and UPC through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remainder on EDI capability, administrative fee compliance, and format adherence. Vendors must maintain commercial general liability coverage of $5,000,000 per occurrence, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and accept a 3 percent administrative fee on all contract purchases. The contract term is two years for new vendors, with optional extensions at MMCAP's discretion, and awarded vendors will be provided to wholesalers by May 15, 2026, with agreements effective July 1, 2026. Geographic reach extends across Minnesota and Oregon, with the alliance model positioning the code for activity across cooperative-purchasing networks spanning multiple states.